Streetbeat News

Analyst Ratings

CRWD

Barclays analyst Saket Kalia has maintained an Overweight rating on CrowdStrike Holdings (CRWD) and increased the price target from $300 to $340.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 4:09 pm

CLVT

Barclays analyst Manav Patnaik maintains an Underweight rating on Clarivate (NYSE:CLVT) and lowers the price target from $7 to $6.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 4:08 pm

ZNTL

Zentalis Pharmaceuticals' stock price increased following Wedbush's decision to maintain a Neutral rating but raise its price target from $12 to $15.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 4:07 pm

ARRY

Cantor Fitzgerald analyst Derek Soderberg maintains an Overweight rating on Array Technologies (ARRY) but lowers the price target from $22 to $18.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 4:06 pm

A

Barclays analyst Jack Meehan maintains an Underweight rating on Agilent Technologies (NYSE:A) and raises the price target from $120 to $125.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 4:06 pm

LUNR

Cantor Fitzgerald analyst Andres Sheppard has reiterated an Overweight rating on Intuitive Machines (NASDAQ:LUNR), maintaining a $13 price target.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 4:04 pm

ACAD

Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on ACADIA Pharmaceuticals (ACAD) and maintained a $42 price target.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 4:03 pm

XNCR

Analysts have recently updated their ratings and price targets for Xencor (NASDAQ:XNCR), showing a mix of bullish sentiments but with a decrease in the average 12-month price target from $44.33 to $37.5, indicating a 15.41% decrease. The company, a clinical-stage biopharmaceutical firm, has shown significant revenue growth and strong financial performance, with a notable net margin and ROE. Despite the lowered price targets, Xencor's financial health and market position remain robust.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 4:01 pm

LNW

Light & Wonder (NASDAQ:LNW) has been analyzed by 4 analysts, showing a mix of bullish and somewhat bullish ratings. The average 12-month price target is $106.25, reflecting a 10.68% increase from the previous target. The company, a major player in electronic gaming machines and mobile games, shows strong financial performance with a notable revenue growth rate of 12.81% and impressive net margin and ROE figures. Analysts from Susquehanna, Truist Securities, JP Morgan, and Benchmark have recently raised their price targets for LNW.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 4:01 pm

FSK

FS KKR Capital (NYSE:FSK) has received indifferent ratings from 5 analysts in the past three months, with all maintaining a neutral stance in the last 30 days. The 12-month price targets show a decrease to an average of $19.6 from $20.50. Analysts from RBC Capital, Truist Securities, JP Morgan, Hovde Group, and Wells Fargo have adjusted their price targets, reflecting recent market conditions and company performance. FS KKR Capital, a business development company, has shown impressive revenue growth and net margin but faces challenges in ROE, ROA, and high debt levels.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 4:01 pm